Flucelvax Quadrivalent vaccine — Competitive Intelligence Brief

Flucelvax Quadrivalent vaccine (Flucelvax Quadrivalent vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology.

phase 3 Inactivated influenza vaccine Immunology Biologic

Target snapshot

Flucelvax Quadrivalent vaccine (Flucelvax Quadrivalent vaccine) — Tan Tock Seng Hospital. Flucelvax Quadrivalent is an inactivated influenza vaccine produced using cell culture technology that stimulates immune response against four strains of influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flucelvax Quadrivalent vaccine TARGET	Flucelvax Quadrivalent vaccine	Tan Tock Seng Hospital	phase 3	Inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Standard-Dose Influenza Vaccine	Standard-Dose Influenza Vaccine	Tor Biering-Sørensen	marketed	Inactivated influenza vaccine
Seasonal trivalent influenza vaccine, Anflu®	Seasonal trivalent influenza vaccine, Anflu®	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
ccIIV4	ccIIV4	Vanderbilt University Medical Center	marketed	Inactivated influenza vaccine
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)
Fluad alone	Fluad alone	Korea University Guro Hospital	marketed	Inactivated influenza vaccine with adjuvant	Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class